myc p53  (Sino Biological)


Bioz Verified Symbol Sino Biological is a verified supplier
Bioz Manufacturer Symbol Sino Biological manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93
    Name:
    p53 cDNA ORF Clone Mouse N Myc tag
    Description:
    Full length Clone DNA of Mouse transformation related protein 53 with N terminal Myc tag
    Catalog Number:
    MG50534-NM
    Price:
    195.0
    Category:
    cDNA Clone
    Applications:
    Stable or Transient mammalian expression
    Size:
    1Unit
    Product Aliases:
    bbl cDNA ORF Clone Mouse, bfy cDNA ORF Clone Mouse, bhy cDNA ORF Clone Mouse, p53 cDNA ORF Clone Mouse, Tp53 cDNA ORF Clone Mouse, Trp53 cDNA ORF Clone Mouse
    Molecule Name:
    TP53,bfy,p53,
    Buy from Supplier


    Structured Review

    Sino Biological myc p53
    p53 cDNA ORF Clone Mouse N Myc tag
    Full length Clone DNA of Mouse transformation related protein 53 with N terminal Myc tag
    https://www.bioz.com/result/myc p53/product/Sino Biological
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    myc p53 - by Bioz Stars, 2021-04
    93/100 stars

    Images

    1) Product Images from "Circular RNA CDR1as disrupts the p53/MDM2 complex to inhibit Gliomagenesis"

    Article Title: Circular RNA CDR1as disrupts the p53/MDM2 complex to inhibit Gliomagenesis

    Journal: Molecular Cancer

    doi: 10.1186/s12943-020-01253-y

    CDR1as functions in a p53-dependent manner. a , b Ectopic expression ( a ), and knock-down ( b ) of CDR1as in HCT116 cells in which p53 is intact (HCT116 p53+/+ ) or absent (HCT116 p53−/− ). c , d Colony formation assays for HCT116 p53+/+ cells and HCT116 p53−/− cells in which CDR1as is ectopically expressed ( c ) or knocked down ( d ). e Flow cytometric cell cycle assays (left) and apoptosis assays (right) for the indicated cells transfected with CDR1as expressing plasmid (or control plasmid). f Flow cytometric cell cycle assays (left) and apoptosis assays (right) for the indicated cells transfected with siCDR1as-1 (or siNC). * p
    Figure Legend Snippet: CDR1as functions in a p53-dependent manner. a , b Ectopic expression ( a ), and knock-down ( b ) of CDR1as in HCT116 cells in which p53 is intact (HCT116 p53+/+ ) or absent (HCT116 p53−/− ). c , d Colony formation assays for HCT116 p53+/+ cells and HCT116 p53−/− cells in which CDR1as is ectopically expressed ( c ) or knocked down ( d ). e Flow cytometric cell cycle assays (left) and apoptosis assays (right) for the indicated cells transfected with CDR1as expressing plasmid (or control plasmid). f Flow cytometric cell cycle assays (left) and apoptosis assays (right) for the indicated cells transfected with siCDR1as-1 (or siNC). * p

    Techniques Used: Expressing, Transfection, Plasmid Preparation

    CDR1as serves as a protective machinery to preserve p53 function against DNA damage in U87MG cells. a Western blot analysis of p53 and p21 expression (left); and RT-qPCR analysis of CDR1as expression (right) in U87MG cells after 48 h treatment with DOXO, VP16 or DMSO (as control). b Western blot analysis of p53 and p21 expression (left); and densitometric analysis of p53 expression normalized to GAPDH (right) in U87MG cells transfected with siCDR1as-1 or siNC after 48 h treatment of DOXO or DMSO. c Flow cytometric analysis of cell cycle in U87MG cells transfected with different siCDR1as or siNC after 48 h treatment of DOXO or DMSO. d Flow cytometric analysis of apoptosis in U87MG cells transfected with siCDR1as-1 or siNC after 48 h treatment of DOXO or DMSO. e IF analysis of γH2A.X (DNA damage marker) in U87MG cells transfected with different siCDR1as or siNC after 48 h treatment of DOXO or DMSO (left); quantification of number of γH2A.X positive cells with equal or more than 10 γH2A.X foci/nucleus (right). * p
    Figure Legend Snippet: CDR1as serves as a protective machinery to preserve p53 function against DNA damage in U87MG cells. a Western blot analysis of p53 and p21 expression (left); and RT-qPCR analysis of CDR1as expression (right) in U87MG cells after 48 h treatment with DOXO, VP16 or DMSO (as control). b Western blot analysis of p53 and p21 expression (left); and densitometric analysis of p53 expression normalized to GAPDH (right) in U87MG cells transfected with siCDR1as-1 or siNC after 48 h treatment of DOXO or DMSO. c Flow cytometric analysis of cell cycle in U87MG cells transfected with different siCDR1as or siNC after 48 h treatment of DOXO or DMSO. d Flow cytometric analysis of apoptosis in U87MG cells transfected with siCDR1as-1 or siNC after 48 h treatment of DOXO or DMSO. e IF analysis of γH2A.X (DNA damage marker) in U87MG cells transfected with different siCDR1as or siNC after 48 h treatment of DOXO or DMSO (left); quantification of number of γH2A.X positive cells with equal or more than 10 γH2A.X foci/nucleus (right). * p

    Techniques Used: Western Blot, Expressing, Quantitative RT-PCR, Transfection, Marker

    p53 physically interacts with CDR1as indicating glioma prognosis. a Heatmap of 30 most enriched lncRNAs binding to p53 protein determined by RIP-seq. b Validation of 30 candidate lncRNAs binding to p53 protein by RIP-qPCR. c Plots of the correlation between the scores of p53 pathway gene sets and expression of candidate lncRNAs in glioma samples in the CGGA cohort. d CDR1as expression in glioma with different WHO grades in the CGGA cohort. e , f Kaplan-Meier curves of the overall survival ( e ) and ROC curves ( f ) of glioma patients in the CGGA cohort. g RT-qPCR assays of CDR1as expression in glioma samples collected by ourselves. h Mapping of RIP-seq reads back to genomic locus of CDR1as . i Validation of the p53- CDR1as interaction by CHIRP. j Co-localization analysis of p53 and CDR1as in U87MG cells using protein IF and RNA FISH assays respectively. ns, no significance; * p
    Figure Legend Snippet: p53 physically interacts with CDR1as indicating glioma prognosis. a Heatmap of 30 most enriched lncRNAs binding to p53 protein determined by RIP-seq. b Validation of 30 candidate lncRNAs binding to p53 protein by RIP-qPCR. c Plots of the correlation between the scores of p53 pathway gene sets and expression of candidate lncRNAs in glioma samples in the CGGA cohort. d CDR1as expression in glioma with different WHO grades in the CGGA cohort. e , f Kaplan-Meier curves of the overall survival ( e ) and ROC curves ( f ) of glioma patients in the CGGA cohort. g RT-qPCR assays of CDR1as expression in glioma samples collected by ourselves. h Mapping of RIP-seq reads back to genomic locus of CDR1as . i Validation of the p53- CDR1as interaction by CHIRP. j Co-localization analysis of p53 and CDR1as in U87MG cells using protein IF and RNA FISH assays respectively. ns, no significance; * p

    Techniques Used: Binding Assay, Real-time Polymerase Chain Reaction, Expressing, Quantitative RT-PCR, Fluorescence In Situ Hybridization

    CDR1as up-regulates expression of p53 protein by inhibiting its ubiquitination in U87MG cells. a Western blot analysis of p53 and its targets (left); and validation of RNA levels of CDR1as , TP53 , MDM2 , CDKN1A and PUMA by RT-qPCR (right) in U87MG cells transfected with increasing concentrations of plasmid encoding CDR1as . b Western blot analysis of p53 and its targets (left); and validation of RNA levels of CDR1as , TP53 , MDM2 , CDKN1A and PUMA by RT-qPCR (right) in U87MG cells transfected with different siCDR1as or siNC. c Western blot analysis of p53 and its targets in CDR1as knocked-down U87MG cells treated with Nutlin3 or DMSO. d Luciferase reporter assays for p53 transcription activity in U87MG cells transfected with increasing concentrations of plasmid encoding CDR1as (left); and in U87MG cells transfected with different siCDR1as or siNC (right). e , f Immunoblot of p53 and MDM2 protein and quantification of p53 relative level at the indicated time in U87MG cells transfected with plasmid encoding CDR1as or control plasmid ( e ); and in U87MG cells transfected with siCDR1as-1 or siNC ( f ) after CHX treatment to block protein synthesis. g Immunoblot of p53 ubiquitination in U87MG cells co-transfected with the plasmids encoding HA-ubiquitin ( HA-Ub ), Myc-MDM2 and CDR1as after MG132 treatment (left); and validation of CDR1as expression by RT-qPCR (right). h Immunoblot of p53 ubiquitination in CDR1as knocked-down (or siNC treated) U87MG cells transfected with the plasmids encoding HA-Ub and Myc-MDM2 after MG132 treatment (left); and validation of CDR1as expression by RT-qPCR (right). * p
    Figure Legend Snippet: CDR1as up-regulates expression of p53 protein by inhibiting its ubiquitination in U87MG cells. a Western blot analysis of p53 and its targets (left); and validation of RNA levels of CDR1as , TP53 , MDM2 , CDKN1A and PUMA by RT-qPCR (right) in U87MG cells transfected with increasing concentrations of plasmid encoding CDR1as . b Western blot analysis of p53 and its targets (left); and validation of RNA levels of CDR1as , TP53 , MDM2 , CDKN1A and PUMA by RT-qPCR (right) in U87MG cells transfected with different siCDR1as or siNC. c Western blot analysis of p53 and its targets in CDR1as knocked-down U87MG cells treated with Nutlin3 or DMSO. d Luciferase reporter assays for p53 transcription activity in U87MG cells transfected with increasing concentrations of plasmid encoding CDR1as (left); and in U87MG cells transfected with different siCDR1as or siNC (right). e , f Immunoblot of p53 and MDM2 protein and quantification of p53 relative level at the indicated time in U87MG cells transfected with plasmid encoding CDR1as or control plasmid ( e ); and in U87MG cells transfected with siCDR1as-1 or siNC ( f ) after CHX treatment to block protein synthesis. g Immunoblot of p53 ubiquitination in U87MG cells co-transfected with the plasmids encoding HA-ubiquitin ( HA-Ub ), Myc-MDM2 and CDR1as after MG132 treatment (left); and validation of CDR1as expression by RT-qPCR (right). h Immunoblot of p53 ubiquitination in CDR1as knocked-down (or siNC treated) U87MG cells transfected with the plasmids encoding HA-Ub and Myc-MDM2 after MG132 treatment (left); and validation of CDR1as expression by RT-qPCR (right). * p

    Techniques Used: Expressing, Western Blot, Quantitative RT-PCR, Transfection, Plasmid Preparation, Luciferase, Activity Assay, Blocking Assay

    CDR1as suppresses gliomagenesis of U87MG cells in vitro and in vivo . a-d Colony formation assays ( a ), cell proliferation assays ( b ), flow cytometric cell cycle assays ( c ) and flow cytometric apoptosis assays ( d ) for U87MG cells treated with different siCDR1as or siNC. e Excised tumors from nude mice xenografted with U87MG cells treated with siCDR1as-1 or siNC. f Volume of xenografted tumors derived from U87MG cells treated with siCDR1as-1 or siNC. g Kaplan-Meier curves of the overall survival of nude mice xenografted with U87MG cells treated with siCDR1as-1 or siNC. h IHC assays for xenografted tumors derived from U87MG cells stained with H E, PCNA antibody and p53 antibody respectively. * p
    Figure Legend Snippet: CDR1as suppresses gliomagenesis of U87MG cells in vitro and in vivo . a-d Colony formation assays ( a ), cell proliferation assays ( b ), flow cytometric cell cycle assays ( c ) and flow cytometric apoptosis assays ( d ) for U87MG cells treated with different siCDR1as or siNC. e Excised tumors from nude mice xenografted with U87MG cells treated with siCDR1as-1 or siNC. f Volume of xenografted tumors derived from U87MG cells treated with siCDR1as-1 or siNC. g Kaplan-Meier curves of the overall survival of nude mice xenografted with U87MG cells treated with siCDR1as-1 or siNC. h IHC assays for xenografted tumors derived from U87MG cells stained with H E, PCNA antibody and p53 antibody respectively. * p

    Techniques Used: In Vitro, In Vivo, Mouse Assay, Derivative Assay, Immunohistochemistry, Staining

    CDR1as directly binds with the DBD region of p53 and disrupts the p53/MDM2 complex. a A schema showing four constructs containing full-length or different domains of p53. b RIP-qPCR analysis of CDR1as binding with the indicated p53 constructs. c IP analysis of interaction between MDM2 and p53 in U87MG cells transfected with increasing concentrations of plasmid encoding CDR1as . d IP analysis of interaction between MDM2 and p53 in U87MG cells co-transfected with plasmids encoding CDR1as , Myc-p53 or Myc-MDM2 . e-h IP analysis of interaction between MDM2 and the indicated p53 constructs in MEF DKO ( p53 −/− ; MDM2 −/− ) cells co-transfected with plasmids encoding CDR1as , HA-MDM2 , and the indicated p53 constructs. * p
    Figure Legend Snippet: CDR1as directly binds with the DBD region of p53 and disrupts the p53/MDM2 complex. a A schema showing four constructs containing full-length or different domains of p53. b RIP-qPCR analysis of CDR1as binding with the indicated p53 constructs. c IP analysis of interaction between MDM2 and p53 in U87MG cells transfected with increasing concentrations of plasmid encoding CDR1as . d IP analysis of interaction between MDM2 and p53 in U87MG cells co-transfected with plasmids encoding CDR1as , Myc-p53 or Myc-MDM2 . e-h IP analysis of interaction between MDM2 and the indicated p53 constructs in MEF DKO ( p53 −/− ; MDM2 −/− ) cells co-transfected with plasmids encoding CDR1as , HA-MDM2 , and the indicated p53 constructs. * p

    Techniques Used: Construct, Real-time Polymerase Chain Reaction, Binding Assay, Transfection, Plasmid Preparation

    Related Articles

    other:

    Article Title: Circular RNA CDR1as disrupts the p53/MDM2 complex to inhibit Gliomagenesis
    Article Snippet: Plasmids of Myc-p53 , Myc-MDM2 , PCDH-p53 and HA-Ub were a gift of Dr. Zhang Lingqiang.

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93
    Sino Biological myc p53
    CDR1as functions in a <t>p53-dependent</t> manner. a , b Ectopic expression ( a ), and knock-down ( b ) of CDR1as in HCT116 cells in which p53 is intact (HCT116 p53+/+ ) or absent (HCT116 p53−/− ). c , d Colony formation assays for HCT116 p53+/+ cells and HCT116 p53−/− cells in which CDR1as is ectopically expressed ( c ) or knocked down ( d ). e Flow cytometric cell cycle assays (left) and apoptosis assays (right) for the indicated cells transfected with CDR1as expressing plasmid (or control plasmid). f Flow cytometric cell cycle assays (left) and apoptosis assays (right) for the indicated cells transfected with siCDR1as-1 (or siNC). * p
    Myc P53, supplied by Sino Biological, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/myc p53/product/Sino Biological
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    myc p53 - by Bioz Stars, 2021-04
    93/100 stars
      Buy from Supplier

    90
    Sino Biological danio rerio tp53 transcript variant 3 gene orf cdna clone expression plasmid n myc tag
    CDR1as functions in a <t>p53-dependent</t> manner. a , b Ectopic expression ( a ), and knock-down ( b ) of CDR1as in HCT116 cells in which p53 is intact (HCT116 p53+/+ ) or absent (HCT116 p53−/− ). c , d Colony formation assays for HCT116 p53+/+ cells and HCT116 p53−/− cells in which CDR1as is ectopically expressed ( c ) or knocked down ( d ). e Flow cytometric cell cycle assays (left) and apoptosis assays (right) for the indicated cells transfected with CDR1as expressing plasmid (or control plasmid). f Flow cytometric cell cycle assays (left) and apoptosis assays (right) for the indicated cells transfected with siCDR1as-1 (or siNC). * p
    Danio Rerio Tp53 Transcript Variant 3 Gene Orf Cdna Clone Expression Plasmid N Myc Tag, supplied by Sino Biological, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/danio rerio tp53 transcript variant 3 gene orf cdna clone expression plasmid n myc tag/product/Sino Biological
    Average 90 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    danio rerio tp53 transcript variant 3 gene orf cdna clone expression plasmid n myc tag - by Bioz Stars, 2021-04
    90/100 stars
      Buy from Supplier

    N/A
    Full length Clone DNA of Human tumor protein p53 TP53 transcript variant 1 with C terminal Myc tag
      Buy from Supplier

    Image Search Results


    CDR1as functions in a p53-dependent manner. a , b Ectopic expression ( a ), and knock-down ( b ) of CDR1as in HCT116 cells in which p53 is intact (HCT116 p53+/+ ) or absent (HCT116 p53−/− ). c , d Colony formation assays for HCT116 p53+/+ cells and HCT116 p53−/− cells in which CDR1as is ectopically expressed ( c ) or knocked down ( d ). e Flow cytometric cell cycle assays (left) and apoptosis assays (right) for the indicated cells transfected with CDR1as expressing plasmid (or control plasmid). f Flow cytometric cell cycle assays (left) and apoptosis assays (right) for the indicated cells transfected with siCDR1as-1 (or siNC). * p

    Journal: Molecular Cancer

    Article Title: Circular RNA CDR1as disrupts the p53/MDM2 complex to inhibit Gliomagenesis

    doi: 10.1186/s12943-020-01253-y

    Figure Lengend Snippet: CDR1as functions in a p53-dependent manner. a , b Ectopic expression ( a ), and knock-down ( b ) of CDR1as in HCT116 cells in which p53 is intact (HCT116 p53+/+ ) or absent (HCT116 p53−/− ). c , d Colony formation assays for HCT116 p53+/+ cells and HCT116 p53−/− cells in which CDR1as is ectopically expressed ( c ) or knocked down ( d ). e Flow cytometric cell cycle assays (left) and apoptosis assays (right) for the indicated cells transfected with CDR1as expressing plasmid (or control plasmid). f Flow cytometric cell cycle assays (left) and apoptosis assays (right) for the indicated cells transfected with siCDR1as-1 (or siNC). * p

    Article Snippet: Plasmids of Myc-p53 , Myc-MDM2 , PCDH-p53 and HA-Ub were a gift of Dr. Zhang Lingqiang.

    Techniques: Expressing, Transfection, Plasmid Preparation

    CDR1as serves as a protective machinery to preserve p53 function against DNA damage in U87MG cells. a Western blot analysis of p53 and p21 expression (left); and RT-qPCR analysis of CDR1as expression (right) in U87MG cells after 48 h treatment with DOXO, VP16 or DMSO (as control). b Western blot analysis of p53 and p21 expression (left); and densitometric analysis of p53 expression normalized to GAPDH (right) in U87MG cells transfected with siCDR1as-1 or siNC after 48 h treatment of DOXO or DMSO. c Flow cytometric analysis of cell cycle in U87MG cells transfected with different siCDR1as or siNC after 48 h treatment of DOXO or DMSO. d Flow cytometric analysis of apoptosis in U87MG cells transfected with siCDR1as-1 or siNC after 48 h treatment of DOXO or DMSO. e IF analysis of γH2A.X (DNA damage marker) in U87MG cells transfected with different siCDR1as or siNC after 48 h treatment of DOXO or DMSO (left); quantification of number of γH2A.X positive cells with equal or more than 10 γH2A.X foci/nucleus (right). * p

    Journal: Molecular Cancer

    Article Title: Circular RNA CDR1as disrupts the p53/MDM2 complex to inhibit Gliomagenesis

    doi: 10.1186/s12943-020-01253-y

    Figure Lengend Snippet: CDR1as serves as a protective machinery to preserve p53 function against DNA damage in U87MG cells. a Western blot analysis of p53 and p21 expression (left); and RT-qPCR analysis of CDR1as expression (right) in U87MG cells after 48 h treatment with DOXO, VP16 or DMSO (as control). b Western blot analysis of p53 and p21 expression (left); and densitometric analysis of p53 expression normalized to GAPDH (right) in U87MG cells transfected with siCDR1as-1 or siNC after 48 h treatment of DOXO or DMSO. c Flow cytometric analysis of cell cycle in U87MG cells transfected with different siCDR1as or siNC after 48 h treatment of DOXO or DMSO. d Flow cytometric analysis of apoptosis in U87MG cells transfected with siCDR1as-1 or siNC after 48 h treatment of DOXO or DMSO. e IF analysis of γH2A.X (DNA damage marker) in U87MG cells transfected with different siCDR1as or siNC after 48 h treatment of DOXO or DMSO (left); quantification of number of γH2A.X positive cells with equal or more than 10 γH2A.X foci/nucleus (right). * p

    Article Snippet: Plasmids of Myc-p53 , Myc-MDM2 , PCDH-p53 and HA-Ub were a gift of Dr. Zhang Lingqiang.

    Techniques: Western Blot, Expressing, Quantitative RT-PCR, Transfection, Marker

    p53 physically interacts with CDR1as indicating glioma prognosis. a Heatmap of 30 most enriched lncRNAs binding to p53 protein determined by RIP-seq. b Validation of 30 candidate lncRNAs binding to p53 protein by RIP-qPCR. c Plots of the correlation between the scores of p53 pathway gene sets and expression of candidate lncRNAs in glioma samples in the CGGA cohort. d CDR1as expression in glioma with different WHO grades in the CGGA cohort. e , f Kaplan-Meier curves of the overall survival ( e ) and ROC curves ( f ) of glioma patients in the CGGA cohort. g RT-qPCR assays of CDR1as expression in glioma samples collected by ourselves. h Mapping of RIP-seq reads back to genomic locus of CDR1as . i Validation of the p53- CDR1as interaction by CHIRP. j Co-localization analysis of p53 and CDR1as in U87MG cells using protein IF and RNA FISH assays respectively. ns, no significance; * p

    Journal: Molecular Cancer

    Article Title: Circular RNA CDR1as disrupts the p53/MDM2 complex to inhibit Gliomagenesis

    doi: 10.1186/s12943-020-01253-y

    Figure Lengend Snippet: p53 physically interacts with CDR1as indicating glioma prognosis. a Heatmap of 30 most enriched lncRNAs binding to p53 protein determined by RIP-seq. b Validation of 30 candidate lncRNAs binding to p53 protein by RIP-qPCR. c Plots of the correlation between the scores of p53 pathway gene sets and expression of candidate lncRNAs in glioma samples in the CGGA cohort. d CDR1as expression in glioma with different WHO grades in the CGGA cohort. e , f Kaplan-Meier curves of the overall survival ( e ) and ROC curves ( f ) of glioma patients in the CGGA cohort. g RT-qPCR assays of CDR1as expression in glioma samples collected by ourselves. h Mapping of RIP-seq reads back to genomic locus of CDR1as . i Validation of the p53- CDR1as interaction by CHIRP. j Co-localization analysis of p53 and CDR1as in U87MG cells using protein IF and RNA FISH assays respectively. ns, no significance; * p

    Article Snippet: Plasmids of Myc-p53 , Myc-MDM2 , PCDH-p53 and HA-Ub were a gift of Dr. Zhang Lingqiang.

    Techniques: Binding Assay, Real-time Polymerase Chain Reaction, Expressing, Quantitative RT-PCR, Fluorescence In Situ Hybridization

    CDR1as up-regulates expression of p53 protein by inhibiting its ubiquitination in U87MG cells. a Western blot analysis of p53 and its targets (left); and validation of RNA levels of CDR1as , TP53 , MDM2 , CDKN1A and PUMA by RT-qPCR (right) in U87MG cells transfected with increasing concentrations of plasmid encoding CDR1as . b Western blot analysis of p53 and its targets (left); and validation of RNA levels of CDR1as , TP53 , MDM2 , CDKN1A and PUMA by RT-qPCR (right) in U87MG cells transfected with different siCDR1as or siNC. c Western blot analysis of p53 and its targets in CDR1as knocked-down U87MG cells treated with Nutlin3 or DMSO. d Luciferase reporter assays for p53 transcription activity in U87MG cells transfected with increasing concentrations of plasmid encoding CDR1as (left); and in U87MG cells transfected with different siCDR1as or siNC (right). e , f Immunoblot of p53 and MDM2 protein and quantification of p53 relative level at the indicated time in U87MG cells transfected with plasmid encoding CDR1as or control plasmid ( e ); and in U87MG cells transfected with siCDR1as-1 or siNC ( f ) after CHX treatment to block protein synthesis. g Immunoblot of p53 ubiquitination in U87MG cells co-transfected with the plasmids encoding HA-ubiquitin ( HA-Ub ), Myc-MDM2 and CDR1as after MG132 treatment (left); and validation of CDR1as expression by RT-qPCR (right). h Immunoblot of p53 ubiquitination in CDR1as knocked-down (or siNC treated) U87MG cells transfected with the plasmids encoding HA-Ub and Myc-MDM2 after MG132 treatment (left); and validation of CDR1as expression by RT-qPCR (right). * p

    Journal: Molecular Cancer

    Article Title: Circular RNA CDR1as disrupts the p53/MDM2 complex to inhibit Gliomagenesis

    doi: 10.1186/s12943-020-01253-y

    Figure Lengend Snippet: CDR1as up-regulates expression of p53 protein by inhibiting its ubiquitination in U87MG cells. a Western blot analysis of p53 and its targets (left); and validation of RNA levels of CDR1as , TP53 , MDM2 , CDKN1A and PUMA by RT-qPCR (right) in U87MG cells transfected with increasing concentrations of plasmid encoding CDR1as . b Western blot analysis of p53 and its targets (left); and validation of RNA levels of CDR1as , TP53 , MDM2 , CDKN1A and PUMA by RT-qPCR (right) in U87MG cells transfected with different siCDR1as or siNC. c Western blot analysis of p53 and its targets in CDR1as knocked-down U87MG cells treated with Nutlin3 or DMSO. d Luciferase reporter assays for p53 transcription activity in U87MG cells transfected with increasing concentrations of plasmid encoding CDR1as (left); and in U87MG cells transfected with different siCDR1as or siNC (right). e , f Immunoblot of p53 and MDM2 protein and quantification of p53 relative level at the indicated time in U87MG cells transfected with plasmid encoding CDR1as or control plasmid ( e ); and in U87MG cells transfected with siCDR1as-1 or siNC ( f ) after CHX treatment to block protein synthesis. g Immunoblot of p53 ubiquitination in U87MG cells co-transfected with the plasmids encoding HA-ubiquitin ( HA-Ub ), Myc-MDM2 and CDR1as after MG132 treatment (left); and validation of CDR1as expression by RT-qPCR (right). h Immunoblot of p53 ubiquitination in CDR1as knocked-down (or siNC treated) U87MG cells transfected with the plasmids encoding HA-Ub and Myc-MDM2 after MG132 treatment (left); and validation of CDR1as expression by RT-qPCR (right). * p

    Article Snippet: Plasmids of Myc-p53 , Myc-MDM2 , PCDH-p53 and HA-Ub were a gift of Dr. Zhang Lingqiang.

    Techniques: Expressing, Western Blot, Quantitative RT-PCR, Transfection, Plasmid Preparation, Luciferase, Activity Assay, Blocking Assay

    CDR1as suppresses gliomagenesis of U87MG cells in vitro and in vivo . a-d Colony formation assays ( a ), cell proliferation assays ( b ), flow cytometric cell cycle assays ( c ) and flow cytometric apoptosis assays ( d ) for U87MG cells treated with different siCDR1as or siNC. e Excised tumors from nude mice xenografted with U87MG cells treated with siCDR1as-1 or siNC. f Volume of xenografted tumors derived from U87MG cells treated with siCDR1as-1 or siNC. g Kaplan-Meier curves of the overall survival of nude mice xenografted with U87MG cells treated with siCDR1as-1 or siNC. h IHC assays for xenografted tumors derived from U87MG cells stained with H E, PCNA antibody and p53 antibody respectively. * p

    Journal: Molecular Cancer

    Article Title: Circular RNA CDR1as disrupts the p53/MDM2 complex to inhibit Gliomagenesis

    doi: 10.1186/s12943-020-01253-y

    Figure Lengend Snippet: CDR1as suppresses gliomagenesis of U87MG cells in vitro and in vivo . a-d Colony formation assays ( a ), cell proliferation assays ( b ), flow cytometric cell cycle assays ( c ) and flow cytometric apoptosis assays ( d ) for U87MG cells treated with different siCDR1as or siNC. e Excised tumors from nude mice xenografted with U87MG cells treated with siCDR1as-1 or siNC. f Volume of xenografted tumors derived from U87MG cells treated with siCDR1as-1 or siNC. g Kaplan-Meier curves of the overall survival of nude mice xenografted with U87MG cells treated with siCDR1as-1 or siNC. h IHC assays for xenografted tumors derived from U87MG cells stained with H E, PCNA antibody and p53 antibody respectively. * p

    Article Snippet: Plasmids of Myc-p53 , Myc-MDM2 , PCDH-p53 and HA-Ub were a gift of Dr. Zhang Lingqiang.

    Techniques: In Vitro, In Vivo, Mouse Assay, Derivative Assay, Immunohistochemistry, Staining

    CDR1as directly binds with the DBD region of p53 and disrupts the p53/MDM2 complex. a A schema showing four constructs containing full-length or different domains of p53. b RIP-qPCR analysis of CDR1as binding with the indicated p53 constructs. c IP analysis of interaction between MDM2 and p53 in U87MG cells transfected with increasing concentrations of plasmid encoding CDR1as . d IP analysis of interaction between MDM2 and p53 in U87MG cells co-transfected with plasmids encoding CDR1as , Myc-p53 or Myc-MDM2 . e-h IP analysis of interaction between MDM2 and the indicated p53 constructs in MEF DKO ( p53 −/− ; MDM2 −/− ) cells co-transfected with plasmids encoding CDR1as , HA-MDM2 , and the indicated p53 constructs. * p

    Journal: Molecular Cancer

    Article Title: Circular RNA CDR1as disrupts the p53/MDM2 complex to inhibit Gliomagenesis

    doi: 10.1186/s12943-020-01253-y

    Figure Lengend Snippet: CDR1as directly binds with the DBD region of p53 and disrupts the p53/MDM2 complex. a A schema showing four constructs containing full-length or different domains of p53. b RIP-qPCR analysis of CDR1as binding with the indicated p53 constructs. c IP analysis of interaction between MDM2 and p53 in U87MG cells transfected with increasing concentrations of plasmid encoding CDR1as . d IP analysis of interaction between MDM2 and p53 in U87MG cells co-transfected with plasmids encoding CDR1as , Myc-p53 or Myc-MDM2 . e-h IP analysis of interaction between MDM2 and the indicated p53 constructs in MEF DKO ( p53 −/− ; MDM2 −/− ) cells co-transfected with plasmids encoding CDR1as , HA-MDM2 , and the indicated p53 constructs. * p

    Article Snippet: Plasmids of Myc-p53 , Myc-MDM2 , PCDH-p53 and HA-Ub were a gift of Dr. Zhang Lingqiang.

    Techniques: Construct, Real-time Polymerase Chain Reaction, Binding Assay, Transfection, Plasmid Preparation